CIK 0001623526
- Non-accelerated filer
- Smaller reporting company
Stoke Therapeutics, Inc.
Sign in to watch- Ticker
- STOK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 471144582
- Phone
- +1 781-430-8200
- Business address
- 45 WIGGINS AVENUE, BEDFORD, MA, 01730
- Former names
- ASOthera Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $403,975
- in 4 filings, $404K under 10b5-1 plans
Net −$403,975. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-11-02 | Nash Huw M. COO & CBO | Sale | −3,164 | $36.59 | $116K | 2,536 |
| 2020-11-02 | Nash Huw M. COO & CBO | Sale | −2,536 | $37.98 | $96K | 0 |
| 2020-11-02 | Nash Huw M. COO & CBO | Exercise or conversion · Employee Stock Option (Right to Buy) | −5,700 | 150,211 | ||
| 2020-10-19 | Liau Gene EVP Research & Preclinical Dev | Exercise or conversion | +30,497 | $0.60 | $18K | 43,997 |
| 2020-10-19 | Liau Gene EVP Research & Preclinical Dev | Exercise or conversion | +1,503 | $2.19 | $3K | 45,500 |
| 2020-10-19 | Liau Gene EVP Research & Preclinical Dev | Sale | −24,775 | $37.64 | $933K | 20,725 |
| 2020-10-19 | Liau Gene EVP Research & Preclinical Dev | Sale | −7,225 | $38.42 | $278K | 13,500 |
| 2020-10-19 | Liau Gene EVP Research & Preclinical Dev | Exercise or conversion · Employee Stock Option (right to buy) | −30,497 | 96,069 | ||
| 2020-10-19 | Liau Gene EVP Research & Preclinical Dev | Exercise or conversion · Employee Stock Option (right to buy) | −1,503 | 70,386 | ||
| 2020-10-16 | Liau Gene EVP Research & Preclinical Dev | Exercise or conversion | +5,851 | $0.60 | $4K | 19,351 |
| 2020-10-16 | Liau Gene EVP Research & Preclinical Dev | Sale | −5,851 | $40.00 | $234K | 13,500 |
| 2020-10-16 | Liau Gene EVP Research & Preclinical Dev | Exercise or conversion · Employee Stock Option (right to buy) | −5,851 | 126,566 | ||
| 2020-10-13 | Liau Gene EVP Research & Preclinical Dev | Exercise or conversion | +1,649 | $0.60 | $989 | 15,149 |
| 2020-10-13 | Liau Gene EVP Research & Preclinical Dev | Sale | −1,649 | $40.00 | $66K | 13,500 |
| 2020-10-13 | Liau Gene EVP Research & Preclinical Dev | Exercise or conversion · Employee Stock Option (right to buy) | −1,649 | 132,417 | ||
| 2020-10-01 | Nash Huw M. COO & CBO | Exercise or conversion | +5,700 | $2.19 | $12K | 5,700 |
| 2020-10-01 | Nash Huw M. COO & CBO | Sale | −3,400 | $34.33 | $117K | 2,300 |
| 2020-10-01 | Nash Huw M. COO & CBO | Sale | −2,300 | $34.86 | $80K | 0 |
| 2020-10-01 | Nash Huw M. COO & CBO | Exercise or conversion · Employee Stock Option (Right to Buy) | −5,700 | 155,911 | ||
| 2020-09-09 | Nash Huw M. COO & CBO | Exercise or conversion | +17,201 | $2.19 | $38K | 17,201 |
Page 29 of 35 · 681 trades